Vincent Lo Re1, Kevin Haynes2, Kimberly A Forde3, David S Goldberg4, James D Lewis3, Dena M Carbonari2, Kimberly B F Leidl5, K Rajender Reddy6, Melissa S Nezamzadeh2, Jason Roy2, Daohang Sha5, Amy R Marks7, Jolanda De Boer7, Jennifer L Schneider7, Brian L Strom8, Douglas A Corley7. 1. Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: vincentl@mail.med.upenn.edu. 2. Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 5. Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 6. Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 7. Division of Research, Kaiser Permanente Northern California, Oakland, California. 8. Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Rutgers Biomedical & Health Sciences, Rutgers, the State University of New Jersey, Newark, New Jersey.
Abstract
BACKGROUND & AIMS: Few studies have evaluated the ability of laboratory tests to predict risk of acute liver failure (ALF) among patients with drug-induced liver injury (DILI). We aimed to develop a highly sensitive model to identify DILI patients at increased risk of ALF. We compared its performance with that of Hy's Law, which predicts severity of DILI based on levels of alanine aminotransferase or aspartate aminotransferase and total bilirubin, and validated the model in a separate sample. METHODS: We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver aminotransferase levels above the upper limit of normal, and no pre-existing liver disease. Thirty ALF events were confirmed by medical record review. Logistic regression was used to develop prognostic models for ALF based on laboratory results measured at DILI diagnosis. External validation was performed in a sample of 76 patients with DILI at the University of Pennsylvania. RESULTS: Hy's Law identified patients that developed ALF with a high level of specificity (0.92) and negative predictive value (0.99), but low level of sensitivity (0.68) and positive predictive value (0.02). The model we developed, comprising data on platelet count and total bilirubin level, identified patients with ALF with a C statistic of 0.87 (95% confidence interval [CI], 0.76-0.96) and enabled calculation of a risk score (Drug-Induced Liver Toxicity ALF Score). We found a cut-off score that identified patients at high risk patients for ALF with a sensitivity value of 0.91 (95% CI, 0.71-0.99) and a specificity value of 0.76 (95% CI, 0.75-0.77). This cut-off score identified patients at high risk for ALF with a high level of sensitivity (0.89; 95% CI, 0.52-1.00) in the validation analysis. CONCLUSIONS: Hy's Law identifies patients with DILI at high risk for ALF with low sensitivity but high specificity. We developed a model (the Drug-Induced Liver Toxicity ALF Score) based on platelet count and total bilirubin level that identifies patients at increased risk for ALF with high sensitivity.
BACKGROUND & AIMS: Few studies have evaluated the ability of laboratory tests to predict risk of acute liver failure (ALF) among patients with drug-induced liver injury (DILI). We aimed to develop a highly sensitive model to identify DILI patients at increased risk of ALF. We compared its performance with that of Hy's Law, which predicts severity of DILI based on levels of alanine aminotransferase or aspartate aminotransferase and total bilirubin, and validated the model in a separate sample. METHODS: We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver aminotransferase levels above the upper limit of normal, and no pre-existing liver disease. Thirty ALF events were confirmed by medical record review. Logistic regression was used to develop prognostic models for ALF based on laboratory results measured at DILI diagnosis. External validation was performed in a sample of 76 patients with DILI at the University of Pennsylvania. RESULTS: Hy's Law identified patients that developed ALF with a high level of specificity (0.92) and negative predictive value (0.99), but low level of sensitivity (0.68) and positive predictive value (0.02). The model we developed, comprising data on platelet count and total bilirubin level, identified patients with ALF with a C statistic of 0.87 (95% confidence interval [CI], 0.76-0.96) and enabled calculation of a risk score (Drug-Induced Liver Toxicity ALF Score). We found a cut-off score that identified patients at high risk patients for ALF with a sensitivity value of 0.91 (95% CI, 0.71-0.99) and a specificity value of 0.76 (95% CI, 0.75-0.77). This cut-off score identified patients at high risk for ALF with a high level of sensitivity (0.89; 95% CI, 0.52-1.00) in the validation analysis. CONCLUSIONS: Hy's Law identifies patients with DILI at high risk for ALF with low sensitivity but high specificity. We developed a model (the Drug-Induced Liver Toxicity ALF Score) based on platelet count and total bilirubin level that identifies patients at increased risk for ALF with high sensitivity.
Authors: Robert J Fontana; Paul H Hayashi; Jiezhun Gu; K Rajender Reddy; Huiman Barnhart; Paul B Watkins; Jose Serrano; William M Lee; Naga Chalasani; Andrew Stolz; Timothy Davern; Jayant A Talwakar Journal: Gastroenterology Date: 2014-03-27 Impact factor: 22.682
Authors: Vincent Lo Re; Dena M Carbonari; Kimberly A Forde; David Goldberg; James D Lewis; Kevin Haynes; Kimberly B F Leidl; Rajender K Reddy; Jason Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley Journal: Pharmacoepidemiol Drug Saf Date: 2015-04-10 Impact factor: 2.890
Authors: David S Goldberg; Kimberly A Forde; Dena M Carbonari; James D Lewis; Kimberly B F Leidl; K Rajender Reddy; Kevin Haynes; Jason Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley; Vincent Lo Re Journal: Gastroenterology Date: 2015-02-28 Impact factor: 22.682
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Mercedes Robles-Diaz; M Isabel Lucena; Neil Kaplowitz; Camilla Stephens; Inmaculada Medina-Cáliz; Andres González-Jimenez; Eugenia Ulzurrun; Ana F Gonzalez; M Carmen Fernandez; Manuel Romero-Gómez; Miguel Jimenez-Perez; Miguel Bruguera; Martín Prieto; Fernando Bessone; Nelia Hernandez; Marco Arrese; Raúl J Andrade Journal: Gastroenterology Date: 2014-04-01 Impact factor: 22.682
Authors: D Nicholas Bateman; James W Dear; H K Ruben Thanacoody; Simon H L Thomas; Michael Eddleston; Euan A Sandilands; Judy Coyle; Jamie G Cooper; Aryelly Rodriguez; Isabella Butcher; Steff C Lewis; A D Bastiaan Vliegenthart; Aravindan Veiraiah; David J Webb; Alasdair Gray Journal: Lancet Date: 2013-11-28 Impact factor: 79.321
Authors: Luke Hillman; Michelle Gottfried; Maureen Whitsett; Jorge Rakela; Michael Schilsky; William M Lee; Daniel Ganger Journal: Am J Gastroenterol Date: 2016-04-05 Impact factor: 10.864
Authors: Lunjie Lu; Jun Zhou; Jingying Zhang; Jun Che; Yang Jiao; Yusong Zhang Journal: Evid Based Complement Alternat Med Date: 2016-05-04 Impact factor: 2.629
Authors: Sebastian P Mondaca; Dazhi Liu; Jessica R Flynn; Sandy Badson; Stefan Hamaway; Mrinal M Gounder; Danny N Khalil; Alexander E Drilon; Bob T Li; Komal L Jhaveri; Alison M Schram; Katherine E Kargus; Mary Kate Kasler; Natalie M Blauvelt; Neil H Segal; Marinela Capanu; Margaret K Callahan; David M Hyman; Maya Gambarin-Gelwan; James J Harding Journal: Cancer Date: 2020-08-18 Impact factor: 6.860